Table 2.
Comparison between laboratory parameters before and after end of treatment in patients without comorbidities
| Laboratory investigations | Group of patients without comorbidities | Test of significance | p value | |
|---|---|---|---|---|
| Pretreatment (n = 24) | End of treatment (n = 24) | |||
| TLC (k/μL), median (IQ) | 6 (4.47–7.15) | 6.55 (5.30–7.50) | Z = 1.03 | 0.304 |
| HB (g/dL), mean ± SD | 13.11±1.55 | 13.06±2.05 | t = 0.266 | 0.793 |
| Plt (k/μL), median (IQ) | 263.5 (194–295.5) | 272 (218–298) | Z = 0.243 | 0.808 |
| ALT (U/mL), median (IQ) | 42.50 (26–64.75) | 20 (18.00–25.75) | Z = 4.19 | < 0.001* |
| AST (U/mL), median (IQ) | 41.5 (34-53.75) | 24 (21–27.75) | Z = 4.28 | < 0.001* |
| Albumin (gm/dL), mean ± SD | 4.79±0.55 | 4.67±0.43 | t = 0.960 | 0.347 |
| TSB (mg/dL), median (IQ) | 0.65(0.60–0.70) | 0.80 (0.62–1) | Z = 2.29 | 0.022* |
| INR, mean ± SD | 1.01±0.04 | 1.00±0.02 | t = 0.81 | 0.426 |
| Cr (mg/dL), mean ± SD | 0.80±0.13 | 0.75±0.16 | t = 1.135 | 0.268 |
| RBG (mg/dL), median (IQ) | 96 (90.25–105.75) | 88 (81.75–93) | Z=1.93 | 0.065 |
ALT alanine aminotransferase, AST aspartate aminotransferase, Cr creatinine, HB hemoglobin, INR international normalized ratio, IQ interquartile (1st Q–3rd Q), Plt platelets, RBG random blood sugar, t paired t-test, TLC total leucocytic count, TSB total serum bilirubin, Z Wilcoxon signed rank test
*Significant p ≤ 0.05